Greylin Investment Management Inc Has $5.78 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

Greylin Investment Management Inc trimmed its holdings in Eli Lilly and Company (NYSE:LLYFree Report) by 12.4% in the first quarter, Holdings Channel reports. The fund owned 7,425 shares of the company’s stock after selling 1,050 shares during the period. Eli Lilly and Company accounts for about 0.9% of Greylin Investment Management Inc’s portfolio, making the stock its 20th biggest position. Greylin Investment Management Inc’s holdings in Eli Lilly and Company were worth $5,776,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. Versant Capital Management Inc lifted its holdings in shares of Eli Lilly and Company by 1.8% during the first quarter. Versant Capital Management Inc now owns 736 shares of the company’s stock worth $573,000 after purchasing an additional 13 shares during the period. Moseley Investment Management Inc. raised its position in Eli Lilly and Company by 0.4% during the 1st quarter. Moseley Investment Management Inc. now owns 3,890 shares of the company’s stock worth $3,027,000 after purchasing an additional 14 shares during the last quarter. CGN Advisors LLC grew its position in shares of Eli Lilly and Company by 1.4% in the 1st quarter. CGN Advisors LLC now owns 1,001 shares of the company’s stock valued at $779,000 after buying an additional 14 shares during the last quarter. Twin Peaks Wealth Advisors LLC increased its stake in shares of Eli Lilly and Company by 2.0% in the first quarter. Twin Peaks Wealth Advisors LLC now owns 718 shares of the company’s stock valued at $559,000 after buying an additional 14 shares during the period. Finally, Pitti Group Wealth Management LLC raised its position in shares of Eli Lilly and Company by 0.8% during the first quarter. Pitti Group Wealth Management LLC now owns 1,673 shares of the company’s stock worth $1,271,000 after acquiring an additional 14 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of LLY stock traded up $5.21 during trading hours on Thursday, hitting $808.12. 3,024,199 shares of the company’s stock were exchanged, compared to its average volume of 3,006,071. The company has a market capitalization of $768.05 billion, a PE ratio of 119.02, a PEG ratio of 1.75 and a beta of 0.37. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. Eli Lilly and Company has a 12-month low of $419.80 and a 12-month high of $820.60. The business’s 50 day simple moving average is $764.43 and its 200-day simple moving average is $690.85.

Eli Lilly and Company (NYSE:LLYGet Free Report) last issued its earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The company had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. During the same quarter last year, the company earned $1.62 EPS. The firm’s revenue was up 26.0% compared to the same quarter last year. On average, equities research analysts anticipate that Eli Lilly and Company will post 13.78 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, June 10th. Investors of record on Thursday, May 16th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 0.64%. The ex-dividend date of this dividend is Wednesday, May 15th. Eli Lilly and Company’s dividend payout ratio is presently 76.58%.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Citigroup boosted their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Barclays increased their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a report on Wednesday, February 7th. Argus boosted their price objective on Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research note on Tuesday, May 14th. Finally, BMO Capital Markets raised their price objective on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 1st. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus price target of $769.53.

Get Our Latest Analysis on LLY

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Recommended Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.